The Japanese pharmaceutical company, Takeda, has announced positive data from the first interim analysis of its pivotal trial investigating ixazomib as a potential treatment for relapsed and/or refractory myeloma. The results showed a significant improvement in progression free survival in patients receiving ixazomib in combination with Revlimid and dexamethasone compared to those receiving Revlimid and dexamethasone only. Ixazomib is the first oral proteasome of its type to be investigated in Phase III trials and is also being studied in AL amyloidosis and other malignancies. On the basis of these data, the company has announced it will be seeking licensing approval from relevant regulatory bodies around the world.


Read full article